"10.1371_journal.pone.0105110","plos one","2014-09-02T00:00:00Z","Sven Schmiedl; Rainald Fischer; Luisa Ibáñez; Joan Fortuny; Olaf H Klungel; Robert Reynolds; Roman Gerlach; Martin Tauscher; Petra Thürmann; Joerg Hasford; Marietta Rottenkolber","Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany; Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany; Pneumologische Praxis München-Pasing, Munich, Germany; Fundació Institut Català de Farmacologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Novartis Farmaceutica S.A., Barcelona, Spain; Utrecht Institute for Pharmaceutical Sciences, Division Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands; Epidemiology, Pfizer, New York, New York, United States of America; National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany; Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Munich, Germany","Conceived and designed the experiments: SS RF LI JF OK RR RG MT PT JH MR. Analyzed the data: MR SS RF RG MT PT JH. Wrote the paper: SS MR RF LI JF OK RR RG MT PT JH.","RF, LI, OK, RG, MT, JH, and MR have no conflicts of interest. PT and SS report personal lecture fees from Rottapharm Madaus (Cologne, Germany). RR is employed by Pfizer belonging to EFPIA (European Federation of Pharmaceutical Industries and Association) member companies in the IMI JU and costs related to their part in the research were carried by the respective company as in-kind contribution under the IMI JU scheme. JF is employed by Novartis Farmaceutica S.A., Barcelona, Spain belonging to EFPIA (European Federation of Pharmaceutical Industries and Association) member companies in the IMI JU and costs related to their part in the research were carried by the respective company as in-kind contribution under the IMI JU scheme. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","09","Sven Schmiedl","SS",11,TRUE,11,NA,7,11,TRUE,TRUE,FALSE,0,NA,FALSE
